{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T04:21:09Z","timestamp":1776399669490,"version":"3.51.2"},"reference-count":31,"publisher":"Elsevier BV","issue":"15","license":[{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,3,29]],"date-time":"2024-03-29T00:00:00Z","timestamp":1711670400000},"content-version":"am","delay-in-days":363,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2023,4]]},"DOI":"10.1016\/j.vaccine.2023.03.005","type":"journal-article","created":{"date-parts":[[2023,3,8]],"date-time":"2023-03-08T02:12:33Z","timestamp":1678241553000},"page":"2427-2429","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":26,"title":["Antibody dependent disease enhancement (ADE) after COVID-19 vaccination and beta glucans as a safer strategy in management"],"prefix":"10.1016","volume":"41","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0591-1228","authenticated-orcid":false,"given":"Nobunao","family":"Ikewaki","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9477-7467","authenticated-orcid":false,"given":"Gene","family":"Kurosawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gary A.","family":"Levy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Senthilkumar","family":"Preethy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samuel J.K.","family":"Abraham","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2023.03.005_b0005","unstructured":"WHO Coronavirus (COVID-19) Dashboard. https:\/\/covid19.who.int\/."},{"key":"10.1016\/j.vaccine.2023.03.005_b0010","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1111\/tmi.13503","article-title":"COVID-19 vaccine research and development: ethical issues","volume":"26","author":"Wibawa","year":"2021","journal-title":"Trop Med Int Health"},{"key":"10.1016\/j.vaccine.2023.03.005_b0015","unstructured":"COVID-19 vaccine tracker. https:\/\/www.raps.org\/news-and-articles\/news-articles\/2020\/3\/covid-19-vaccine-tracker."},{"key":"10.1016\/j.vaccine.2023.03.005_b0020","unstructured":"COVID-19 vaccine tracker- https:\/\/covid19.trackvaccines.org."},{"key":"10.1016\/j.vaccine.2023.03.005_b0025","unstructured":"Tracking Coronavirus Vaccinations Around the World \u2013 The New York Times - https:\/\/www.nytimes.com\/interactive\/2021\/world\/covid-vaccinations-tracker.html."},{"key":"10.1016\/j.vaccine.2023.03.005_b0030","article-title":"Prospects for a safe COVID-19 vaccine","author":"Haynes","year":"2020120948","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.vaccine.2023.03.005_b0035","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1038\/s41564-020-00789-5","article-title":"Antibody-dependent enhancement and SARS-CoV-2 vaccines and therapies","volume":"5","author":"Lee","year":"2020","journal-title":"Nat Microbiol"},{"key":"10.1016\/j.vaccine.2023.03.005_b0040","doi-asserted-by":"crossref","unstructured":"Maemura T, Kuroda M, Armbrust T, Yamayoshi S, Halfmann PJ, Kawaoka Y. Antibody-Dependent Enhancement of SARS-CoV-2 Infection Is Mediated by the IgG Receptors Fc\u03b3RIIA and Fc\u03b3RIIIA but Does Not Contribute to Aberrant Cytokine Production by Macrophages. mBio. 2021 Oct 26;12(5):e0198721.","DOI":"10.1128\/mBio.01987-21"},{"key":"10.1016\/j.vaccine.2023.03.005_b0045","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1038\/s41586-020-2538-8","article-title":"A perspective on potential antibody-dependent enhancement of SARS-CoV-2","volume":"584","author":"Arvin","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.vaccine.2023.03.005_b0050","doi-asserted-by":"crossref","first-page":"10382","DOI":"10.1128\/JVI.00747-06","article-title":"Murine Hepatitis Virus Strain 1 Produces a Clinically Relevant Model of Severe Acute Respiratory Syndrome in A\/J Mice","volume":"80","author":"De Albuquerque","year":"2006","journal-title":"J Virology"},{"key":"10.1016\/j.vaccine.2023.03.005_b0055","doi-asserted-by":"crossref","first-page":"12201","DOI":"10.1128\/JVI.06048-11","article-title":"A double-inactivated severe acute respiratory syndrome coronavirus vaccine provides incomplete protection in mice and induces increased eosinophilic proinflammatory pulmonary response upon challenge","volume":"85","author":"Bolles","year":"2011","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2023.03.005_b0060","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.640093","article-title":"Two Different Antibody-Dependent Enhancement (ADE) Risks for SARS-CoV-2 Antibodies","volume":"12","author":"Ricke","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.vaccine.2023.03.005_b0065","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.3389\/fimmu.2018.01963","article-title":"New Vaccine Technologies to Combat Outbreak Situations","volume":"9","author":"Rauch","year":"2018","journal-title":"Front Immunol"},{"key":"10.1016\/j.vaccine.2023.03.005_b0070","doi-asserted-by":"crossref","unstructured":"Sch\u00e4fer A, Alam SM, Wiehe K, Lu X, Parks R, Sutherland LL, et al. The functions of SARS-CoV-2 neutralizing and infection-enhancing antibodies in vitro and in mice and nonhuman primates.bioRxiv preprint. 2020doi:https:\/\/doi.org\/10.1101\/2020.12.31.424729.","DOI":"10.1101\/2020.12.31.424729"},{"key":"10.1016\/j.vaccine.2023.03.005_b0075","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1038\/s41577-020-00434-6","article-title":"Immunological considerations for COVID-19 vaccine strategies","volume":"20","author":"Jeyanathan","year":"2020","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.vaccine.2023.03.005_b0080","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1001\/jama.2020.15543","article-title":"Effect of an Inactivated Vaccine Against SARS-CoV-2 on Safety and Immunogenicity Outcomes: Interim Analysis of 2 Randomized Clinical Trials","volume":"324","author":"Xia","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.vaccine.2023.03.005_b0085","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1038\/s41564-020-0770-5","article-title":"A dynamic nomenclature proposal for SARS-CoV-2 lineages to assist genomic epidemiology","volume":"5","author":"Rambaut","year":"2020","journal-title":"Nat Microbiol"},{"issue":"11","key":"10.1016\/j.vaccine.2023.03.005_b0090","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1177\/01410768211053006","article-title":"The costs of coronavirus vaccines and their pricing","volume":"114","author":"Light","year":"2021","journal-title":"J R Soc Med"},{"key":"10.1016\/j.vaccine.2023.03.005_b0095","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.632478","article-title":"The BCG Vaccine for COVID-19: First Verdict and Future Directions","volume":"12","author":"Gonzalez-Perez","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.vaccine.2023.03.005_b0100","doi-asserted-by":"crossref","first-page":"5378","DOI":"10.3390\/molecules25225378","article-title":"Development of Fish Immunity and the Role of \u03b2-Glucan in Immune Responses","volume":"25","author":"Rodrigues","year":"2020","journal-title":"Molecules"},{"key":"10.1016\/j.vaccine.2023.03.005_b0105","doi-asserted-by":"crossref","first-page":"1782","DOI":"10.3389\/fimmu.2020.01782","article-title":"Could the Induction of Trained Immunity by \u03b2-Glucan Serve as a Defense Against COVID-19?","volume":"11","author":"Geller","year":"2020","journal-title":"Front Immunol"},{"key":"10.1016\/j.vaccine.2023.03.005_b0110","doi-asserted-by":"crossref","DOI":"10.1080\/21645515.2021.1880210","article-title":"\u03b2-Glucans: Wide-spectrum Immune-balancing Food-supplement-based Enteric (\u03b2-WIFE) Vaccine Adjuvant Approach to COVID-19","volume":"17","author":"Ikewaki","year":"2021","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.vaccine.2023.03.005_b0115","first-page":"11:1782","author":"Ikewaki","year":"2020","journal-title":"J Front Immunol"},{"key":"10.1016\/j.vaccine.2023.03.005_b0120","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1111\/j.1600-065X.2009.00793.x","article-title":"Beta-glucan recognition by the innate immune system","volume":"230","author":"Goodridge","year":"2009","journal-title":"Immunol Rev"},{"issue":"6","key":"10.1016\/j.vaccine.2023.03.005_b0125","doi-asserted-by":"crossref","first-page":"9745","DOI":"10.3390\/molecules20069745","article-title":"Molecular Interactions of \u03b2-(1\u21923)-Glucans with Their Receptors","volume":"20","author":"Legentil","year":"2015","journal-title":"Molecules (Basel, Switzerland)"},{"key":"10.1016\/j.vaccine.2023.03.005_b0130","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1177\/1753425915595874","article-title":"Cellular and molecular mechanisms of fungal \u03b2-(1\u21926)-glucan in macrophages","volume":"21","author":"Noss","year":"2015","journal-title":"Innate Immun"},{"key":"10.1016\/j.vaccine.2023.03.005_b0135","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2021.112243","article-title":"Beneficial effects of novel aureobasidium pullulans strains produced beta-1,3\u20131,6 glucans on interleukin-6 and D-dimer levels in COVID-19 patients; results of a randomized multiple-arm pilot clinical study","volume":"145","author":"Raghavan","year":"2022","journal-title":"Biomed Pharmacother"},{"key":"10.1016\/j.vaccine.2023.03.005_b0140","doi-asserted-by":"crossref","unstructured":"Pushkala S, Seshayyan S, Theranirajan E, Sudhakar D, Raghavan K, Dedeepiya VD, et al.Efficient control of IL-6, CRP and Ferritin in Covid-19 patients with two variants of Beta-1,3-1,6 glucans in combination, within 15 days in an open-label prospective clinical trial.medRxiv 2021.12.14.21267778;doi: https:\/\/doi.org\/10.1101\/2021.12.14.21267778.","DOI":"10.1101\/2021.12.14.21267778"},{"key":"10.1016\/j.vaccine.2023.03.005_b0145","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1038\/s41586-020-2787-6","article-title":"Animal models for COVID-19","volume":"586","author":"Mu\u00f1oz-Fontela","year":"2020","journal-title":"Nature"},{"issue":"12","key":"10.1016\/j.vaccine.2023.03.005_b0150","article-title":"Animal Models for COVID-19: Hamsters, Mouse, Ferret, Mink, Tree Shrew, and Non-human Primates","volume":"31","author":"Shou","year":"2021","journal-title":"Front Microbiol"},{"issue":"7830","key":"10.1016\/j.vaccine.2023.03.005_b0155","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1038\/s41586-020-2787-6","article-title":"Animal models for COVID-19","volume":"586","author":"Mu\u00f1oz-Fontela","year":"2020","journal-title":"Nature"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X23002529?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X23002529?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T11:24:11Z","timestamp":1759404251000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X23002529"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4]]},"references-count":31,"journal-issue":{"issue":"15","published-print":{"date-parts":[[2023,4]]}},"alternative-id":["S0264410X23002529"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2023.03.005","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2023,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Antibody dependent disease enhancement (ADE) after COVID-19 vaccination and beta glucans as a safer strategy in management","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2023.03.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}